文献速递产科

静脉氨甲环酸预防孕妇产后出血的最佳剂量研究

Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women.
PubMed 文献 · Am J Obstet Gynecol · 2020-11-26

本研究为开放标签剂量探索研究,纳入30名择期剖宫产孕妇,随机接受5、10或15 mg/kg(最大1000 mg)静脉氨甲环酸。结果显示所有剂量在给药后>1小时均达到治疗目标(血药浓度>10 μg/mL且最大溶解<17%),无严重不良事件,乳汁浓度≤母体血浆1%,作者建议未来预防性研究采用600 mg剂量。

要点

  • 择期剖宫产孕妇静脉氨甲环酸5-15 mg/kg均达到治疗目标。
  • 无静脉血栓栓塞等严重不良事件,乳汁浓度≤母体血浆1%。
  • 作者建议未来预防产后出血的研究采用600 mg剂量。

核心结论

  • 虽然需要大型随机试验支持氨甲环酸预防产后出血的临床疗效,但作者提出未来疗效研究的最佳剂量为600 mg。

研究设计与样本

  • 开放标签剂量探索研究,纳入30名择期剖宫产孕妇,分为3组分别接受5、10、15 mg/kg(最大1000 mg)静脉氨甲环酸。

主要发现

  • 所有剂量组在给药后>1小时血浆氨甲环酸浓度>10 μg/mL且最大溶解<17%。
  • 5、10、15 mg/kg组的中位估计失血量分别为750、750、700 mL。
  • 血浆凝血酶生成未随氨甲环酸浓度升高而增加,D-二聚体变化组间无差异。
  • 乳汁氨甲环酸浓度为母体血浆浓度的1%或更低。

关键数值与推荐

  • 治疗目标定义为血浆氨甲环酸浓度>10 μg/mL且最大溶解<17%。
  • 最低剂量组平均接受448±87 mg氨甲环酸。
  • 纳入标准为≥34周妊娠且肾功能正常。

临床怎么用

  • 对于择期剖宫产孕妇,可考虑使用静脉氨甲环酸预防产后出血,但需等待大型随机试验验证临床疗效。

局限性

  • 样本量小(30例),需大型随机试验支持临床疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Every 2 minutes, there is a pregnancy-related death worldwide, with one-third caused by severe postpartum hemorrhage. Although international trials demonstrated the efficacy of 1000 mg tranexamic acid in treating postpartum hemorrhage, to the best of our knowledge, there are no dose-finding studies of tranexamic acid on pregnant women for postpartum hemorrhage prevention. OBJECTIVE: This study aimed to determine the optimal tranexamic acid dose needed to prevent postpartum hemorrhage. STUDY DESIGN: We enrolled 30 pregnant women undergoing scheduled cesarean delivery in an open-label, dose ranging study. Subjects were divided into 3 cohorts receiving 5, 10, or 15 mg/kg (maximum, 1000 mg) of intravenous tranexamic acid at umbilical cord clamping. The inclusion criteria were ≥34 week's gestation and normal renal function. The primary endpoints were pharmacokinetic and pharmacodynamic profiles. Tranexamic acid plasma concentration of >10 μg/mL and maximum lysis of <17% were defined as therapeutic targets independent to the current study. Rotational thromboelastometry of tissue plasminogen activator-spiked samples was used to evaluate pharmacodynamic profiles at time points up to 24 hours after tranexamic acid administration. Safety was assessed by plasma thrombin generation, D-dimer, and tranexamic acid concentrations in breast milk. RESULTS: There were no serious adverse events including venous thromboembolism. Plasma concentrations of tranexamic acid increased in a dose-proportional manner. The lowest dose cohort received an average of 448±87 mg tranexamic acid. Plasma tranexamic acid exceeded 10 μg/mL and maximum lysis was <17% at >1 hour after administration for all tranexamic acid doses tested. Median estimated blood loss for cohorts receiving 5, 10, or 15 mg/kg tranexamic acid was 750, 750, and 700 mL, respectively. Plasma thrombin generation did not increase with higher tranexamic acid concentrations. D-dimer changes from baseline were not different among the cohorts. Breast milk tranexamic acid concentrations were 1% or less than maternal plasma concentrations. CONCLUSION: Although large randomized trials are necessary to support the clinical efficacy of tranexamic acid for prophylaxis, we propose an optimal dose of 600 mg in future tranexamic acid efficacy studies to prevent postpartum hemorrhage.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ahmadzia HK, Luban NLC, Li S, et al. Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. Am J Obstet Gynecol. 2020. PMID: 33248975. doi:10.1016/j.ajog.2020.11.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。